Acer Therapeutics — Investor Presentation (August 2022)
37 slides from Acer Therapeutics's investor presentation, Aug 23, 2022
Slide 1: Corporate Presentation
Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Significant Unmet Medical Needs Corporate Presentation August 23, 2022 Nasdaq: ACER Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Corporate Overview
Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with significant unmet medical needs Offices: Newton, MA and Bend, OR Headcount: 41 Founded: December 2013 Public: September 20
Slide 4: Investment Highlights
4 Investment Highlights ACER Acer’s pipeline includes three clinical development programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD) ACER-801 (osanetant) for the treatment of i
Slide 5: Clinical Pipeline
5 Clinical Pipeline ACER $ Additional capital required to support ACER-001 development (UCDs), and planned ACER-001 (MSUD), ACER-801 and EDSIVO™ clinical trials beyond Q4 2022 1 PDUFA target action date does not guarantee timing of decision by FDA PDUFA Date: Jan. 15, 2023 $ $ $ $,1
Slide 6: Urea cycle disorders (UCDs) overview and ACER-001 opportunity
Urea cycle disorders (UCDs): a group of metabolic genetic diseases that lead to toxic build-up of ammonia (NH4+) 6 Current Treatment Options Disease Overview The Opportunity ACER-001 Profile Overview 1 Payer claims data on file 2 https://ir.horizontherapeutics.com/static-files/47f395cb-4d8e-47a7-ba2
Slide 7: Acer received a Complete Response Letter (CRL) to its NDA
Acer received a Complete Response Letter (CRL) to its NDA in late Q2 2022 The CRL indicates that the FDA cannot approve the NDA in its current form The CRL states: “[The FDA’s] field investigator could not complete inspection of [Acer’s third-party contract packaging manufacturer], because the facil
Slide 8: ACER-001 Urea Cycle Disorders (UCDs)
8 ACER-001 Urea Cycle Disorders (UCDs) Ah Mew N, et al.. Urea cycle disorders overview. Gene Reviews. Seattle, Washington: University of Washington, Seattle; 1993. Lichter-Knoecki U., et al. Ornithine Transcarbamylase Deficiency, Gene Reviews. Seattle, Washington: University of Washington, Seattle;
Slide 9: ACER-001 Mechanism of Action
9 Berry S, et al. Molecular Genetics and Metabolism 125 (2018) 251–257. ACER-001 Mechanism of Action NH4+ α-Ketoglutarate Glutamate Glutamine GPB PBA Buphenyl ® (sodium phenylbutyrate) PAA PAGN Ravicti® (glycerol phenylbutyrate) Oral Liquid Ester hydrolysis/ Pancreatic Lipases β-oxidation Urine Excr
Slide 10: ACER-001 Currently Marketed Treatment Options (US)
10 ACER-001 Currently Marketed Treatment Options (US)1 Sodium Phenylbutyrate (BUPHENYL®, generics): Aversive taste and odor2; considered unpalatable by some patients3 64% of patients reported it is difficult to take because of taste3 Physicians reported that 25-33% of patients took less than target
Slide 11: ACER-001 Product Differentiation
11 ACER-001 Product Differentiation ACER-001 is a proprietary and novel formulation of NaPB powder that has shown bioequivalence to existing NaPB but with a pH-sensitive polymer coating that is designed to minimize dissolution over 5 minutes after preparation1 1 Acer Therapeutics. Data on File. 2021
Slide 12: PHEBURANE is approved by FDA for UCDs but not currently marketed
12 1 PHEBURANE is approved by FDA for UCDs but not currently marketed in the US (based on available information) * Subject to FDA approval ** Shchelochkov et al., Molecular Genetics and Metabolism Reports 8 (2016) 43-47 *** RAVICTI® and BUPHENYL® pppy is based on patient weight and WAC price ACER-00
Slide 13: ACER-001 Value Proposition
13 ACER-001 Value Proposition ACER-001 Novel polymer-coated formulation for oral administration Designed for palatability1 Convenient portable, premeasured packaging + additional dosing options 505(b)(2) NDA submission: trials showed ACER-001 has similar relative bioavailability to sodium phenylbuty
Slide 14: Maple Syrup Urine Disease (MSUD) overview
Maple Syrup Urine Disease (MSUD): a rare, life-threatening metabolic disorder caused by a deficiency in an enzyme complex that metabolizes branched chain ketoacids, the breakdown products of the three branched-chain amino acids (BCAAs), leucine, valine, and isoleucine 14 Current Treatment Options Di
Slide 15: ACER-001 IP / Exclusivities
15 ACER-001 IP / Exclusivities Intellectual Property: Issued patents: US Patent 11,154,521 covering claims re: formulation compositions of matter (expires in 2036) US Patent 11,202,767 covering claims re: certain methods of use (expires in 2036) US Patent 10,092,532 covering claims re: methods of mo
Slide 16: Agreement with Relief Therapeutics
Signed Collaboration and License Agreement Q1 2021 To date, Acer has received $35.0M of funding Acer retained development and commercialization rights in the U.S., Canada, Brazil, Turkey and Japan Split net profits from Acer’s territories (60% to Relief; 40% to Acer) Relief licensed rights for the r
Slide 17: ACER-801 Vasomotor symptoms overview
Vasomotor symptoms (VMS) are caused by a decrease in estrogen signaling in the brain, resulting in menopausal-like symptoms (hot flashes, night sweats, etc.) 17 ACER-801 Mechanism of Action Disease Overview The Opportunity ACER-801 Profile Overview 1 Rada G., et al. Cochrane Database Syst Rev. 2010
Slide 18: Vasomotor Symptoms (VMS)
VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) 18 Vasomotor Symptoms (VMS) Roth A, et al. The Oncologist, Oct 2003, vol.8 no.5 474-487. Levine B. http://www.everydayhealth.com/menopause
Slide 19: Induced Vasomotor Symptoms (iVMS)
19 Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 years, 4
Slide 20: ACER-801 Mechanism of Action
Neurokinin B (NKB;TAC2 gene) is a stimulatory molecule that activates the neurokinin 3 receptor (NK3R) found in the arcuate nucleus (ARC) of the hypothalamus and the central amygdala regions of the brain The hypothalamus controls body homeostasis and the kisspeptin/ neurokinin B/dynorphin (KNDy) neu
Slide 21: Clinical POC in VMS: NK3R Antagonist
21 Clinical POC in VMS: NK3R Antagonist Depypere H, et al. ENDO2017 Fezolinetant is a NK3R antagonist being developed by Astellas for moderate-to-severe VMS ACER-801 At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Daily Hot F
Slide 22: Clinical POC in VMS: NK1,3R Antagonist
22 Clinical POC in VMS: NK1,3R Antagonist Trower M, et al. Menopause. 2020 May; 27(5): 498–505. Elinzanetant (NT-814) is a dual NK1,3R antagonist for the treatment of vasomotor symptoms in postmenopausal women ACER-801 Mean (+/-SE) Daily Frequency A Placebo 50 mg 100 mg 150 mg 300 mg Day -8 -7 -6 -5
Slide 23: iVMS: The Unmet Need
iVMS are well documented with the use of cancer therapies and certain surgical procedures and VMS appear immediately and can be severe Estrogen is contraindicated for the management of VMS in patients with hormone positive (HR+) tumors, including breast and prostate tumors A non-hormonal treatment f
Slide 24: ACER-801 Development Plan
Q1 2022: Began patient enrollment in Phase 2a, randomized, double-blind, placebo-controlled, dose-ranging trial (NCT05325775) in Q1 2022: Primary objective: Evaluate the safety profile of ACER-801 at different doses Evaluate the pharmacokinetic (PK) profile of ACER-801 at different doses Secondary o
Slide 25: EDSIVO Overview and Opportunity
Current Treatment Options Autosomal dominant connective tissue disorder of collagen synthesis caused by mutations in the COL3A1 gene for type III procollagen Characterized by arterial aneurysms, dissections and/or ruptures in arteries and hollow organs (intestines, uterus, lungs, etc.) Often fatal:
Slide 26: Vascular Ehlers-Danlos Syndrome (vEDS)
Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Hollow Organs (e.g., gastrointestinal, uterine) Autosomal dominant (50%); spontaneous mutations (50%) Diagno
Slide 27: Efficacy: 76% reduction in risk of events in COL3A1+ patients
Efficacy: 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ pat
Slide 28: DiSCOVER trial design
DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) trial design:* A Phase 3, U.S.-based, randomized, double-blind, decentralized (virtual) clinical trial to compare the efficacy of celiprolol to placebo in the treatment of patients with COL3A1-positive vEDS Primary objectiv
Slide 29: Financial Overview
29 Cash as of June 30, 2022: $14.5M Subsequent gross proceeds of $0.6M from ATM and equity line Expected to have sufficient capital to fund current operations into Q4 2022 If ACER-001 receives U.S. FDA approval1 by December 31, 2022, $42.5M could be funded through loan from Marathon, extending avail
Slide 30: Reference Slides
Reference Slides 30
Slide 31: Leadership Team
Leadership Team Chris Schelling 23 years; strategic commercial dev. & orphan BiOMARIN a 1 Quarts, MD 20+ years; clin, dev., medical & regulatory affairs | BIOMARIN Faye Hayden cor 20+ years; drug dev, delivery, mfg. & alliance mgt. | LONZGA Harry Palin) 25+ years; corporate & finance experience No&v
Slide 32: MSUD inborn error of BCAA metabolism
MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of
Slide 33: ACER-001 MSUD: Clinical POC
33 ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at Baylor College of Medicine – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Result
Slide 34: ACER-2820 host-directed antiviral overview
Host-directed therapy – restores the cellular stress response, blocking ribosome biogenesis and translation-elongation of viral mRNA in infected cells Mechanism of Action Potential treatment for DNA and RNA-replicating viruses, including cytomegalovirus, Zika, dengue, Ebola, COVID-19 and other virus
Slide 35: ACER-2820 Broad-spectrum, Antiviral Activity
35 ACER-2820 Broad-spectrum, Antiviral Activity
Slide 36: ACER-2820 Nanomolar Potency In Vitro
36 ACER-2820 Nanomolar Potency In Vitro EC50 = concentration of a drug that gives half-maximal response. IC50 = concentration of an inhibitor where the response is reduced by half CC50 = 50% cytotoxic concentration *EC50 / CC50 values = μM (unless otherwise noted) **For reference, the EC50 of remdes
Slide 37: ACER-2820 In Vivo Efficacy Data
37 ACER-2820 In Vivo Efficacy Data A b C B SJL mice Number of ZIKV particles per 1 μg RNA sample 101 102 103 104 Emetine - + Day 0 Day 6 n.d. * Serum viral load (NS1 ng/mL) -10000 1000 2000 3000 Ifnar1 -/- mice VC E1 E2 MOCK % Survival BALB/c mice DPBS emetine 1 mg.kg Post-infection (Days) 0 20 40 6
Acer Therapeutics — Investor Presentation (August 2022) on 6ix